Table 2. Distribution of the patients with different all-PRLR and LF-PRLR expression.
| Parameters | All-PRLR, n (%) | LF-PRLR, n (%) | |||||
|---|---|---|---|---|---|---|---|
| Negative/low expression | High expression | P value | Negative expression | Low/high expression | P value | ||
| Age at diagnosis, years | 0.148 | 0.134 | |||||
| ≤50 | 40 (38.8) | 73 (30.8) | 58 (37.4) | 55 (29.7) | |||
| >50 | 63 (61.2) | 164 (69.2) | 97 (62.6) | 130 (70.3) | |||
| Tumor size, mm | 0.513 | 0.271 | |||||
| ≤20 | 34 (33.0) | 87 (36.7) | 60 (38.7) | 61 (33.0) | |||
| >20 | 69 (67.0) | 150 (63.3) | 95 (61.3) | 124 (67.0) | |||
| Histological grading | <0.001 | 0.010 | |||||
| I/II | 44 (42.7) | 154 (65.0) | 102 (65.8) | 96 (51.9) | |||
| III | 59 (57.3) | 83 (35.0) | 53 (34.2) | 89 (48.1) | |||
| Lymphovascular invasion | 0.060 | 0.855 | |||||
| Absence | 78 (75.7) | 155 (65.4) | 107 (69.0) | 126 (68.1) | |||
| Presence | 25 (24.3) | 82 (34.6) | 48 (31.0) | 59 (31.9) | |||
| Axillary nodal metastasis | 0.091 | 0.658 | |||||
| Absence | 55 (53.4) | 103 (43.5) | 70 (45.2) | 88 (47.6) | |||
| Presence | 48 (46.6) | 134 (56.5) | 85 (46.7) | 97 (52.4) | |||
| Staging | 0.209 | 0.296 | |||||
| I/II | 79 (76.7) | 166 (70.0) | 116 (74.8) | 129 (69.7) | |||
| III | 24 (23.3) | 71 (30.0) | 39 (25.2) | 56 (30.3) | |||
| ER | <0.001 | 0.002 | |||||
| Negative | 56 (54.4) | 49 (20.7) | 35 (22.6) | 70 (37.8) | |||
| Positive | 47 (45.6) | 188 (79.3) | 120 (77.4) | 115 (62.2) | |||
| PR | <0.001 | <0.001 | |||||
| Negative | 62 (60.2) | 65 (27.4) | 42 (27.1) | 85 (45.9) | |||
| Positive | 41 (39.8) | 172 (72.6) | 113 (72.9) | 100 (54.1) | |||
| HER2 | 0.120 | <0.001 | |||||
| Negative | 79 (76.7) | 162 (68.4) | 126 (81.3) | 115 (62.2) | |||
| Positive | 24 (23.3) | 75 (31.6) | 29 (18.7) | 70 (37.8) | |||
| Subtype | <0.001 | <0.001 | |||||
| Luminal A and B HER2 negative | 38 (36.9) | 151 (63.7) | 103 (66.5) | 86 (46.5) | |||
| Luminal B HER2 positive | 10 (9.7) | 37 (15.6) | 18 (11.6) | 29 (15.7) | |||
| HER2 overexpression | 14 (13.6) | 38 (16.0) | 11 (7.1) | 41 (22.2) | |||
| Triple negative | 41 (39.8) | 11 (4.6) | 23 (14.8) | 29 (15.7) | |||
All-PRLR, all prolactin receptor isoforms; LF-PRLR, long-form prolactin receptor; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2.